Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2021; 20(02): 164-171
DOI: 10.4103/wjnm.WJNM_95_20
Original Article

Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?

Tarun Jain
Department of Nuclear Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
,
Guman Singh
1   Department of Radiation Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
,
Sumit Goyal
1   Department of Radiation Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
,
Ajay Yadav
2   Department of Medical Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
,
Dinesh Yadav
3   Department of Surgical Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
,
Nitin Khunteta
3   Department of Surgical Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
,
Hemant Malhotra
2   Department of Medical Oncology, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Posttreatment detection of residual/recurrence disease in the head and neck cancers is not an easy task. Treatment induces changes create difficulties in diagnosis on conventional imaging (computed tomography [CT], magnetic resonance imaging) as well as macroscopic inspection (direct laryngoscopy). Hence, we evaluate the diagnostic performance of contract-enhanced F-18 fluorodeoxyglucose positron emission tomography (FDG PET)/CT in restaging of laryngeal carcinoma Postchemotherapy-surgery and/or radiation therapy. We retrospectively analyzed patients of carcinoma larynx (n = 100) who has completed treatment and were referred for FDG PET/CT. Two reviewers performed image analysis to determine recurrence at primary site and/lymph nodes and distant metastases. Receiver operating characteristic (ROC) was used to determine the maximum standardized uptake value (SUVmax) cut off for disease detection. Histopathological examination and clinical or imaging follow-up were taken as gold standard for recurrence. One hundred laryngeal carcinoma patients with mean age of 57.2 years (range of 40–76) were included in the present study. Among the 100 patients, 96 were male and remaining 4 were female. The average interval between completion of treatment and FDG PET/CT scan was 8.5 months (minimum 6 months). Of the 100 patients, FDG PET/CT detected FDG avid lesions in 66 patients. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of FDG PET/CT for residual/recurrence disease detection was 90.3%, 73.7%, 84.8%, 82.3%, and 84.0%, respectively (P < 0.05). In addition, in 10 patients, metachronous primaries were detected (lung-4, thyroid-2, tongue, colon, esophagus, and lymphoma-one each). On ROC curve analysis, SUVmax >6.1 had sensitivity and specificity of 80.6% and 94.7% respectively for detection of recurrent/metastatic disease. FDG PET/CT demonstrates high diagnostic accuracy for detection of residual/recurrent disease in treated laryngeal cancer patients and our findings suggest that this imaging modality should be the first-line diagnostic investigation in this cohort of patients.

Keywords

Fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography - laryngeal carcinoma - metabolic biopsy - metachronous second primary - receiver operating characteristic analysis

Financial support and sponsorship

Nil.




Publication History

Received: 26 August 2020

Accepted: 19 November 2020

Article published online:
24 March 2022

© 2021. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Montero PH, Patel SG. Cancer of the oral cavity. Surg Oncol Clin N Am 2015;24:491-508.
  • 2 Eleftheriadou A, Chalastras T, Ferekidou E, Kyriou L, Yiotakis I, Pappas Z, et al. Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx. Anticancer Res 2006;26:2493-7.
  • 3 Oe A, Kawabe J, Torii K, Kawamura E, Kotani J, Hayashi T, et al. Detection of local residual tumor after laryngeal cancer treatment using FDG-PET. Ann Nucl Med 2007;21:9-13.
  • 4 Bae JS, Roh JL, Lee SW, Kim SB, Kim JS, Lee JH, et al. Laryngeal edema after radiotherapy in patients with squamous cell carcinomas of the larynx and hypopharynx. Oral Oncol 2012;48:853-8.
  • 5 de Bree R, van der Putten L, Hoekstra OS, Kuik DJ, Uyl-de Groot CA, van Tinteren H, et al. A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy. Contemp Clin Trials 2007;28:705-12.
  • 6 Brouwer J, Bodar EJ, De Bree R, Langendijk JA, Castelijns JA, Hoekstra OS, et al. Detecting recurrent laryngeal carcinoma after radiotherapy: Room for improvement. Eur Arch Otorhinolaryngol 2004;261:417-22.
  • 7 Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
  • 8 Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001;23:933-41.
  • 9 Kim HJ, Boyd J, Dunphy F, Lowe V. F-18 FDG PET scan after radiotherapy for early-stage larynx cancer. Clin Nucl Med 1998;23:750-2.
  • 10 van der Putten L, Hoekstra OS, de Bree R, Kuik DJ, Comans EF, Langendijk JA, et al. 2-Deoxy-2[F-18]FDG-PET for detection of recurrent laryngeal carcinoma after radiotherapy: Interobserver variability in reporting. Mol Imaging Biol 2008;10:294-303.
  • 11 Haerle SK, Schmid DT, Ahmad N, Hany TF, Stoeckli SJ. The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma. Oral Oncol 2011;47:653-9.
  • 12 Jones AS, Morar P, Phillip DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995;75:1343-53.
  • 13 Kuriakose MA, Loree TR, Rubenfeld A, Anderson TM, Datta RV, Hill H, et al. Simultaneously presenting head and neck and lung cancer: A diagnostic and treatment dilemma. Laryngoscope 2002;112:120-3.
  • 14 Kim EB, Park Y, Park SJ, Kim DS, Kim JW, Seo HY, et al. Clinical factors related to suspected second primary lung cancer development in patients with head and neck cancer. Cancer Res Treat 2008;40:178-83.
  • 15 Ritoe SC, Krabbe PF, Jansen MM, Festen J, Joosten FB, Kaanders JH, et al. Screening for second primary lung cancer after treatment of laryngeal cancer. Laryngoscope 2002;112:2002-8.
  • 16 Loh KS, Brown DH, Baker JT, Gilbert RW, Gullane PJ, Irish JC. A rational approach to pulmonary screening in newly diagnosed head and neck cancer. Head Neck 2005;27:990-4.
  • 17 Silverman S Jr., Gorsky M, Greenspan D. Tobacco usage in patients with head and neck carcinomas: A follow-up study on habit changes and second primary oral/oropharyngeal cancers. J Am Dent Assoc 1983;106:33-5.
  • 18 Dornfeld K, Hopkins S, Simmons J, Spitz DR, Menda Y, Graham M, et al. Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008;71:386-92.
  • 19 Kitajima K, Suenaga Y, Kanda T, Miyawaki D, Yoshida K, Ejima Y, et al. Prognostic value of FDG PET imaging in patients with laryngeal cancer. PLoS One 2014;9:e96999.
  • 20 Kaida H, Ishibashi M, Kurata S, Uchiyama Y, Tanaka N, Abe T, et al. The utility of FDG-PET for detecting multiple primary cancers in hypopharyngeal cancer patients. Nuklearmedizin 2009;48:179-84.
  • 21 Joshi VM, Wadhwa V, Mukherji SK. Imaging in laryngeal cancers. Indian J Radiol Imaging 2012;22:209-26.
  • 22 Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315-22.
  • 23 Gordin A, Daitzchman M, Doweck I, Yefremov N, Golz A, Keidar Z, et al. Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management. Laryngoscope. 2006; 116:273-8.
  • 24 Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004;130:1361-7.
  • 25 de Bree R, van der Putten L, van Tinteren H, Wedman J, Oyen WJ, Janssen LM, et al. Effectiveness of an (18)F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. Radiother Oncol 2016;118:251-6.